Literature DB >> 17116670

Steady-state pharmacokinetics of micafungin and voriconazole after separate and concomitant dosing in healthy adults.

J Keirns1, T Sawamoto, M Holum, D Buell, W Wisemandle, A Alak.   

Abstract

We assessed the pharmacokinetics and interactions of steady-state micafungin (Mycamine) or placebo with steady-state voriconazole in 35 volunteers. The 90% confidence intervals around the least-squares mean ratios for micafungin pharmacokinetic parameters and placebo-corrected voriconazole pharmacokinetic parameters were within the 80%-to-125% limits, indicating an absence of drug interaction.

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 17116670      PMCID： PMC1797737          DOI： 10.1128/AAC.00673-06

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  13 in total

1.  Antifungal mechanism of FK463 against Candida albicans and Aspergillus fumigatus.

Authors:  Kazuo Hatano; Yoshihiko Morishita; Toru Nakai; Fumiaki Ikeda
Journal:  J Antibiot (Tokyo)       Date:  2002-02       Impact factor: 2.649

2.  Combination therapy in treatment of experimental pulmonary aspergillosis: synergistic interaction between an antifungal triazole and an echinocandin.

Authors:  Vidmantas Petraitis; Ruta Petraitiene; Alia A Sarafandi; Amy M Kelaher; Caron A Lyman; Heather E Casler; Tin Sein; Andreas H Groll; John Bacher; Nilo A Avila; Thomas J Walsh
Journal:  J Infect Dis       Date:  2003-06-04       Impact factor: 5.226

3.  Safety and pharmacokinetics of coadministered voriconazole and anidulafungin.

Authors:  James A Dowell; Jennifer Schranz; Alice Baruch; Grover Foster
Journal:  J Clin Pharmacol       Date:  2005-12       Impact factor: 3.126

4.  Efficacy of FK463, a new lipopeptide antifungal agent, in mouse models of disseminated candidiasis and aspergillosis.

Authors:  F Ikeda; Y Wakai; S Matsumoto; K Maki; E Watabe; S Tawara; T Goto; Y Watanabe; F Matsumoto; S Kuwahara
Journal:  Antimicrob Agents Chemother       Date:  2000-03       Impact factor: 5.191

5.  Efficacy of FK463, a new lipopeptide antifungal agent, in mouse models of pulmonary aspergillosis.

Authors:  S Matsumoto; Y Wakai; T Nakai; K Hatano; T Ushitani; F Ikeda; S Tawara; T Goto; F Matsumoto; S Kuwahara
Journal:  Antimicrob Agents Chemother       Date:  2000-03       Impact factor: 5.191

6.  In vitro antifungal activity of FK463, a new water-soluble echinocandin-like lipopeptide.

Authors:  H Mikamo; Y Sato; T Tamaya
Journal:  J Antimicrob Chemother       Date:  2000-09       Impact factor: 5.790

7.  Efficacy of FK463, a (1,3)-beta-D-glucan synthase inhibitor, in disseminated azole-resistant candida albicans infection in mice.

Authors:  S Maesaki; M A Hossain; Y Miyazaki; K Tomono; T Tashiro; S Kohno
Journal:  Antimicrob Agents Chemother       Date:  2000-06       Impact factor: 5.191

8.  In vitro activities of a new lipopeptide antifungal agent, FK463, against a variety of clinically important fungi.

Authors:  S Tawara; F Ikeda; K Maki; Y Morishita; K Otomo; N Teratani; T Goto; M Tomishima; H Ohki; A Yamada; K Kawabata; H Takasugi; K Sakane; H Tanaka; F Matsumoto; S Kuwahara
Journal:  Antimicrob Agents Chemother       Date:  2000-01       Impact factor: 5.191

9.  Voriconazole, a novel wide-spectrum triazole: oral pharmacokinetics and safety.

Authors:  Lynn Purkins; Nolan Wood; Katie Greenhalgh; Michael J Allen; Stuart D Oliver
Journal:  Br J Clin Pharmacol       Date:  2003-12       Impact factor: 4.335

10.  Effect of food on the pharmacokinetics of multiple-dose oral voriconazole.

Authors:  Lynn Purkins; Nolan Wood; Diane Kleinermans; Katie Greenhalgh; Don Nichols
Journal:  Br J Clin Pharmacol       Date:  2003-12       Impact factor: 4.335
View more
  14 in total

1.  Bronchopulmonary disposition of micafungin in healthy adult volunteers.

Authors:  Anthony M Nicasio; Pamela R Tessier; David P Nicolau; R Fredrick Knauft; John Russomanno; Eric Shore; Joseph L Kuti
Journal:  Antimicrob Agents Chemother       Date:  2008-12-29       Impact factor: 5.191

Review 2.  Micafungin: a review of its use in the prophylaxis and treatment of invasive Candida infections in pediatric patients.

Authors:  Natalie J Carter; Gillian M Keating
Journal:  Paediatr Drugs       Date:  2009       Impact factor: 3.022

3.  Intrapulmonary pharmacokinetics and pharmacodynamics of micafungin in adult lung transplant patients.

Authors:  Thomas J Walsh; Sylvain Goutelle; Roger W Jelliffe; Jeffrey A Golden; Emily A Little; Catherine DeVoe; Diana Mickiene; Maggie Hayes; John E Conte
Journal:  Antimicrob Agents Chemother       Date:  2010-05-03       Impact factor: 5.191

4.  Altered Micafungin Pharmacokinetics in Intensive Care Unit Patients.

Authors:  Vincent J Lempers; Jeroen A Schouten; Nicole G Hunfeld; Angela Colbers; Henk J van Leeuwen; David M Burger; Paul E Verweij; Peter Pickkers; Roger J Brüggemann
Journal:  Antimicrob Agents Chemother       Date:  2015-05-11       Impact factor: 5.191

5.  In vivo pharmacodynamic target investigation for micafungin against Candida albicans and C. glabrata in a neutropenic murine candidiasis model.

Authors:  D R Andes; D J Diekema; M A Pfaller; K Marchillo; J Bohrmueller
Journal:  Antimicrob Agents Chemother       Date:  2008-07-14       Impact factor: 5.191

Review 6.  Micafungin: a review of its use in adults for the treatment of invasive and oesophageal candidiasis, and as prophylaxis against Candida infections.

Authors:  Sarah A Cross; Lesley J Scott
Journal:  Drugs       Date:  2008       Impact factor: 9.546

7.  Clinical and Microbiological Characteristics of Candida guilliermondii and Candida fermentati.

Authors:  Tatsuro Hirayama; Taiga Miyazaki; Yuka Yamagishi; Hiroshige Mikamo; Takashi Ueda; Kazuhiko Nakajima; Yoshio Takesue; Yoshitsugu Higashi; Yoshihiro Yamamoto; Muneyoshi Kimura; Hideki Araoka; Shuichi Taniguchi; Yuichi Fukuda; Yumi Matsuo; Akiko Furutani; Kohei Yamashita; Takahiro Takazono; Tomomi Saijo; Shintaro Shimamura; Kazuko Yamamoto; Yoshifumi Imamura; Koichi Izumikawa; Katsunori Yanagihara; Shigeru Kohno; Hiroshi Mukae
Journal:  Antimicrob Agents Chemother       Date:  2018-05-25       Impact factor: 5.191

8.  Assessment of micafungin loading dosage regimens against Candida spp. in ICU patients by Monte Carlo simulations.

Authors:  Xiaoqing Lu; Gaoqi Xu; Lu Chen; Jingjing Fan; Mengxue Li; Liqin Zhu
Journal:  Eur J Clin Pharmacol       Date:  2020-02-11       Impact factor: 2.953

9.  A Physiologically Based Pharmacokinetic Model of Voriconazole Integrating Time-Dependent Inhibition of CYP3A4, Genetic Polymorphisms of CYP2C19 and Predictions of Drug-Drug Interactions.

Authors:  Xia Li; Sebastian Frechen; Daniel Moj; Thorsten Lehr; Max Taubert; Chih-Hsuan Hsin; Gerd Mikus; Pertti J Neuvonen; Klaus T Olkkola; Teijo I Saari; Uwe Fuhr
Journal:  Clin Pharmacokinet       Date:  2020-06       Impact factor: 6.447

10.  Micafungin in the treatment of invasive candidiasis and invasive aspergillosis.

Authors:  Nathan P Wiederhold; Jason M Cota; Christopher R Frei
Journal:  Infect Drug Resist       Date:  2009-01-12       Impact factor: 4.003
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.